Bespoke Regulatory Pathway & Validation Diagnostic

Launching June 15, 2026. Sold out until launch. Notify list opens now.

the five-second epistemology of: your regulatory affairs director is probably overcautious · your marketing team is probably undercautious · the FDA, ISO, and CE are not the same as safety · the audit is the operational signal, not the certificate · The Dispatch reads the gap between regulatory paperwork and the product working in the world

FREE ADVICE FIRST. THE DISPATCH IS AGGRESSIVE ON REGULATORY OVER-CAUTION AND AGGRESSIVE ON ACTUAL SAFETY.

Two positions to set before you buy. Both are non-negotiable. (See Caveat Emptor Positions 3 and 4.)

One. If your regulatory affairs director, your in-house counsel, or your outside law firm is telling you to delay the launch, scope down the indication, narrow the claim, or sit on the submission because of "FDA risk" — The Dispatch's default position is that they are wrong. The Dispatch reads aggressive marketing claims and defends them against the agency. (Position 3.) If your lawyer is scared, The Dispatch reads the lawyer, not the regulation.

Two. If there is any reason to believe your product is actually hurting people — pull it. Today. Recall it. Take the recall, not the profits. (Position 4.) The Dispatch does not read this as a regulatory question. The Dispatch reads this as an ethical question, and the answer is unambiguous. If your founder is telling you to "monitor and adjust" while there are reports of adverse events, do not buy this engine. Do not buy anything from The Dispatch for this decision. Pull the product and come back when the operational ethics question is resolved.

This diagnostic is for buyers in the middle — not the buyer whose lawyer is scared of nothing, and not the buyer whose product is hurting people. The middle is where The Dispatch does work.

WHAT THE DIAGNOSTIC COVERS.

FDA pathway (510(k), De Novo, PMA, OTC monograph), ISO 13485 (medical device quality management), ISO 9001 (general quality management), CE marking under MDR or other applicable EU regulation, and the audit story behind all of them.

The Dispatch reads ISO before Big Four. The ISO audit is the operational signal. The Big Four financial audit is downstream. The Dispatch does not invert that priority. (See Caveat Emptor on this in the Blackstone engine context — same principle applies to regulatory.)

THE WRITING TEST.

Tell your head of regulatory affairs, quality director, or general counsel to put it in writing. 800 words. Plain English. What pathway are you on. What are the risks. What is the timeline. Why these decisions.

If they produce writing full of "agency discretion," "potential exposure," "on the conservative side" — hit buy. That is the artifact The Dispatch reads against.

If they produce writing that names specific guidance documents, specific predicate devices, specific predicate submissions, and the specific operational decisions that flow from those — closer. Buy the diagnostic anyway. The Dispatch audits the decisions.

If they say "the FDA is unpredictable" — hit buy. The FDA is more predictable than the seminary tells you. The unpredictability is usually the function of how the submission was written.

WHAT THE DIAGNOSTIC NAMES.

• The right pathway — named, against your product and your indication, with the operational reasoning
• The wrong pathway you are currently on, if you are on one — named, with why
• The aggressive position on claims — named, with how to defend it (Position 3)
• The safety questions that are real — named, with the recall logic if it applies (Position 4)
• The ISO 13485 / ISO 9001 audit posture — named, against your actual quality system, not your quality manual
• The CE pathway, if applicable — named, with the MDR or other applicable regulation
• The audit story — ISO audit first, Big Four second
• The specific guidance documents and predicates relevant to your case — named, with the operational implications
• What your lawyer told you that is wrong — named, where applicable
• What your marketing team told you that is wrong in the opposite direction — named, where applicable

48-hour delivery. Cards included.

HOW THIS WORKS.

You click buy. You upload the product description, the current regulatory posture, the law firm memos (if any), the regulatory affairs director's strategy doc (if any), the quality manual (if any). You name the situation: pre-submission, mid-submission, post-clearance, audit prep, complaint trending.

The diagnostic lands in 48 hours. No scoping call. No SOW. No NDA dance. You give the basic requirements. The Dispatch ships.

THE 48-HOUR CLOCK.

You are buying time. Not labor. If the diagnostic needs more time, that is The Dispatch's call.

PART TWO. WHAT HAPPENS AFTER THE DIAGNOSTIC LANDS.

Your regulatory affairs director will not like the diagnostic. If the diagnostic names the current pathway as overcautious, your director will tell you The Dispatch does not understand the agency, the precedent, the relationship with the reviewer, or the historical pattern of FDA enforcement. Fifty reasons. The Dispatch does not show up to defend the diagnostic.

Your outside counsel will really not like the diagnostic. The law firm is billing hours on the cautious pathway. The diagnostic is naming the cautious pathway as bad strategy. The Dispatch does not chase the law firm.

Your founder will love the diagnostic. If the diagnostic names aggressive claims as defensible. The Dispatch does not chase the founder either — the founder loving the diagnostic is fine, but Position 4 still applies. If the founder loves the diagnostic and ignores actual safety signals, the diagnostic does not protect the founder. The founder still has to recall the product if there is real harm. The Dispatch named that on this page. The founder agreed to it by clicking buy.

Your in-house quality team will sometimes love the diagnostic. If the diagnostic names ISO audit posture as already operationally sound, quality knows. The Dispatch names what is real.

This is a blueprint, not a debate. The diagnostic is for you to act on. Part two is your job.

CAVEAT EMPTOR. REFUNDS ARE NARROW. TALK TO YOUR LAWYER BEFORE BUYING.

The Dispatch has standing positions at bespokeontology.com/pages/caveat-emptor. By clicking buy, you agree to them.

Most relevant: Position 3 (legal is probably wrong — overcautious). Position 4 (marketing, sales, founder are wrong in the opposite direction — no alarmists on safety). Position 11 (the board meeting is theater — your regulatory strategy does not land at the board, it lands before it). Position 16 (stakeholders do not exist — if your regulatory strategy needs to clear a cross-functional safety committee plus a stakeholder review plus an external advisory board, the engine is not for you).

Refunds are narrow. The Dispatch refunds genuinely bad work — a misread of a guidance document, a misnamed predicate, a misread of an applicable regulation. The Dispatch does not refund because your law firm told you the agency will react differently than the diagnostic predicts. Reactions are reactions. The diagnostic is the diagnostic.

Talk to your lawyer before buying, not after. (Same lawyer the diagnostic is auditing? Read this page with a different lawyer.)

KNOW WHAT YOU ARE BUYING.

Read the page first. Read every page first.

THE PRICE.

$2,994.99. Five-dollar Substack discount applied. Top-tier FDA law firm: $1,200–$2,500 per hour, often 80–300 hours for an engagement. ISO consulting: $50K–$300K. The Dispatch: $2,994.99 in 48 hours.

Click. Pay. Upload the product, the current posture, the memos.

The diagnostic lands.